RxDoctor Payments Data

Eric Pierson, MD

Nephrology · Wilmington, NCNPI 1538375597

Payments from drug & device makers

$9,462in general payments, 2019–2025

Across 66 payments — averaging $143.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$8K
  • Nxstage Medical, Inc.$392
  • Calliditas Therapeutics US Inc.$352
  • AstraZeneca$304
  • Akebia Therapeutics Inc$146
  • Travere Therapeutics, Inc.$129
  • plus $532 from 12 others

What the payments were for

  • Food & beverage$1,83199%
  • Education$251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,462 in reported general payments places this provider in the 75th percentile of 366 nephrology providers in North Carolina.

See all nephrology providers in North Carolina

Medicare billing

Part B allowed, 2024
$221,143
Medicare patients
577
Services billed
4,237

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sevelamer Carbonate47$12,299
FarxigaDapagliflozin Propanediol11$10,849
LokelmaSodium Zirconium Cyclosilicate16$8,048
Cinacalcet Hcl26$6,502
Calcium Acetate69$5,945
Calcitriol278$3,428
SpsSodium Polystyrene Sulfon/Sorb14$3,389
Gentamicin Sulfate71$2,016
Potassium Citrate ErPotassium Citrate19$1,495
Furosemide229$1,127
Midodrine Hcl16$797
Tacrolimus11$604
Nystatin36$572
Amlodipine Besylate114$555
Carvedilol84$344

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$304$18,89727 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 366 nephrology providers in North Carolina.

Other nephrology in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →